NCT07004868 Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study
| NCT ID | NCT07004868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Tours |
| Condition | Lung Cancer (NSCLC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-06-03 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2025-06-03 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer is the leading cause of cancer-related death in France and globally, with 2.48 million new cases diagnosed in 2022, accounting for nearly 13% of global cancer incidence. Despite recent advances, it remains a major health issue due to late-stage diagnosis and high patient and societal burden. New insights into tumor and immune pathways have led to the development of targeted therapies, including tyrosine kinase inhibitors and therapeutic antibodies. Among these, immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, and durvalumab have significantly improved outcomes for some patients by reactivating T-cell responses. The LCAb (Lung Cancer Antibodies) research project focuses on studying the interindividual variability of clinical response to ICI in lung cancer. These therapies are now used across various lung cancer types and stages, including early and advanced disease. Most ICIs are administered at fixed doses, without considering patient-specific factors as blood concentrations, tumor burden, body weight or nutritional status. The study hypothesizes that fixed dosing may affect treatment response and survival outcomes, highlighting the need for more personalized approaches.
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 18 years * Diagnosis of lung cancer, any histology, any stage * Treatment with Ab ICI, with or without chemotherapy * 1st administration of Ab ICI Exclusion Criteria: * Patient not followed at the CHRU de Tours * Person under protective supervision * Opposition to data processing
Contact & Investigator
Marion FERREIRA, Dr
PRINCIPAL INVESTIGATOR
University Hospital, Tours
Frequently Asked Questions
Who can join the NCT07004868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07004868 currently recruiting?
Yes, NCT07004868 is actively recruiting participants. Contact the research team at marion.ferreira@chu-tours.fr for enrollment information.
Where is the NCT07004868 trial being conducted?
This trial is being conducted at Tours, France.
Who is sponsoring the NCT07004868 clinical trial?
NCT07004868 is sponsored by University Hospital, Tours. The principal investigator is Marion FERREIRA, Dr at University Hospital, Tours. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.